Global Structured-Based Drug Design Market Size Is Projected To Reach USD 9.85 Billion By 2035 | CAGR of 12.30%
Category: HealthcareGlobal Structured-Based Drug Design Market Size Is Projected To Reach USD 9.85 Billion By 2035
According to a research report published by Spherical Insights & Consulting, The Global Structured-Based Drug Design Market Is Expected To Grow From USD 2.75 Billion In 2024 To USD 9.85 Billion By 2035, At A CAGR Of 12.30% During The Forecast Period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On The "Global Structured-Based Drug Design Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Small Molecule Drugs, Biologics, Peptides, and Others), By Technology (Molecular Docking, Homology Modelling, Molecular Dynamics, Virtual Screening, and Others), By Application (Oncology, Infectious Diseases, Neurology, Cardiovascular Diseases, and Others), By End-User (Pharmaceutical Companies, Biotechnology Companies, Academic & Research Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. " Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/structured-based-drug-design-market
The structured-based drug design market refers to the worldwide industry involving the use of 3D structural data of biological targets (i.e. proteins, nucleic acids) for designing, optimizing, and developing new, highly targeted medicine. Structure-based drug design (SBDD) is used in the development of new drugs, involving the use of three-dimensional structures of biological macromolecules, such as proteins or nucleic acids, to guide the design of molecules that can bind to the target protein and modulate its activity. One notable example of the SBDD usage is the development of protease inhibitors for the treatment of HIV, resulting in the development of drugs like saquinavir and ritonavir. Major players are increasingly investing in R&D and expanding partnerships between tech firms, which is driving the market. Biotech industries’ delivering innovation in drug discovery is contributing to promoting market growth. Remodeling structure-based drug design using machine learning is also propelling the market growth. On the contrary, factors like increased cost and the use of complex computational tools are challenging the market growth.
The small molecule drugs segment dominated the market with bout 52.0% share in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the drug type, the structured-based drug design market is divided into small molecule drugs, biologics, peptides, and others. Among these, the small molecule drugs segment dominated the market with about 52.0% share in 2024 and is projected to grow at a substantial CAGR during the forecast period. Molecular interactions between the designed drug and a target’s binding pocket aid in maximizing affinity and specificity, often using X-ray crystallography, NMR, or modelling.
The molecular docking segment accounted for the largest share of over 22.5% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the technology, the structured-based drug design market is divided into molecular docking, homology modelling, molecular dynamics, virtual screening, and others. Among these, the molecular docking segment accounted for the largest share of over 22.5% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Molecular docking is a high-throughput computational technique that predicts the most stable, 3D binding orientation (pose) and affinity of a small-molecule ligand within a target protein’s active site. Because of its versatility, cost-effectiveness, and ability to integrate with other computational methods, the segmental market is driving.
The oncology segment held the largest market share of over 38.0% in 2024 and is projected to grow at a significant CAGR during the forecast period.
Based on the application, the structured-based drug design market is divided into oncology, infectious diseases, neurology, cardiovascular diseases, and others. Among these, the oncology segment held the largest market share of over 38.0% in 2024 and is projected to grow at a significant CAGR during the forecast period. SBDD enables the creation of potent, highly selective inhibitors that disrupt cancer signalling, such as kinases, with fewer side effects. An increasing emphasis on personalized oncology and immune-oncology therapies is driving segmental market growth.
The pharmaceutical companies segment held the largest market share of about 61.0% in 2024 and is projected to grow at a significant CAGR during the forecast period.
Based on the end-user, the structured-based drug design market is divided into pharmaceutical companies, biotechnology companies, academic & research institutes, and others. Among these, the pharmaceutical companies segment held the largest market share of about 61.0% in 2024 and is projected to grow at a significant CAGR during the forecast period. Structure-based drug design in modern pharmaceutical R&D accelerates the drug discovery process by using 3D structural information of biological targets.
North America is expected to hold the majority share of the global structured-based drug design market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of about 44.0% in the global structured-based drug design market during the forecast period. The U.S. is dominating the North America structured-based drug design market, with about 75.0% share within the region, owing to the integration of genAI and the shift towards “computer-driven” discovery model. North America has a robust market ecosystem that includes both cutting-edge startups (including Genesis Therapeutics, Recursion Pharmaceuticals, Atomwise) and major industries (including WuXi AppTec, Charles River Laboratories, Evotec, and Curia) specialize in small molecule discovery. Further, the region's increased R&D investments, rapid adoption of AI/machine learning for reducing discovery time and a heavy burden of chronic diseases are propelling market for structured-based drug design.
Asia Pacific is anticipated to grow at the fastest pace of 16.2% CAGR in the global structured-based drug design market during the forecast period. China is holding the largest share within the Asia Pacific market, driven by a strategic shift from genetic drug manufacturing to high-value, innovative, and AI-driven drug discovery. In the Asia Pacific structured-based drug design market, there is increasing R&D investment by biopharmaceutical companies and an increased prevalence of chronic diseases. Further, the implementation of license agreements between pharma industries and international life sciences investment firms for advancing an extensive pipeline is significantly contributing to promoting market growth.
Major vendors in the global structured-based drug design market are F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Schrödinger, Inc., Astex Pharmaceuticals (Otsuka Pharmaceutical Co., Ltd.), Charles River Laboratories International, Inc., Evotec SE, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In February 2026, Japan-headquartered Nxera Pharma entered into a license agreement with a newly established independent company (NewCo), created by a leading international life sciences investment firm, to advance Nxera’s G protein-coupled receptor (GPCR)-targeted programme.
- In September 2025, Frost & Sullivan announced that Viva Biotech has been given the 2025 APAC Technology Innovation Leadership recognition in the Integrated Intelligent Drug Discovery Industry for its achievements in driving transformative efficiencies in preclinical research and development.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the structured-based drug design market based on the below-mentioned segments:
Global Structured-Based Drug Design Market, By Drug Type
- Small Molecule Drugs
- Biologics
- Peptides
- Others
Global Structured-Based Drug Design Market, By Technology
- Molecular Docking
- Homology Modelling
- Molecular Dynamics
- Virtual Screening
- Others
Global Structured-Based Drug Design Market, By Application
- Oncology
- Infectious Diseases
- Neurology
- Cardiovascular Diseases
- Others
Global Structured-Based Drug Design Market, By End-User
- Pharmaceutical Companies
- Biotechnology Companies
- Academic & Research Institutes
- Others
Global Structured-Based Drug Design Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?